Skip to main navigation Skip to search Skip to main content

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIR as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal

Project: Research

Project Details

StatusActive
Effective start/end date07/1/26 → 06/7/29

Funding

  • Janssen Research and Development LLC: $6,604.00